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HIV/AIDS MAJOR ARTICLE 
Infections wit Ehrlichia chaffeensis 
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Leonard N. Slater,5 Allison M. Liddell,6 Richard S. Buller,6 Gregory A. Storch,6 Thomas P. Monson,' David Rim1and,2 
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The clinical course and laboratory evaluation of 21 patients coinfected with human immunodeficiency virus 
(HIV) and Ehrlichia chaffeensis or Ehrlichia ewingii are reviewed and summarized, including 13 cases of 
ehrlichiosis caused by E. chaffeensis, 4 caused by E. ewingii, and 4 caused by either E. chaffeensis or E. ewingii. 
Twenty patients were male, and the median CD4+ T lymphocyte count was 137 cells/4L. Exposures to infecting 
ticks were linked to recreational pursuits, occupations, and peridomestic activities. For 8 patients, a diagnosis 
of ehrlichiosis was not considered until -4 days after presentation. Severe manifestations occurred more 
frequently among patients infected with E. chaffeensis than they did among patients infected with E. ewingii, 
and all 6 deaths were caused by E. chaffeensis. Ehrlichiosis may be a life-threatening illness in HIV-infected 
persons, and the influence of multiple factors, induding recent changes in the epidemiology and medical 
management of HIV infection, may increase the frequency with which ehrlichioses occur in this patient cohort. 
During the first 2 decades of the AIDS epidemic, a 
diverse collection of pathogens emerged as causes of 
opportunistic diseases in persons infected with HIV. 
During this same period, 3 species of tickborne bacteria 
in the genus Ehrlichia, namely Ehrlichia chaffeensis, the 
as-yet-unnamed agent of human granulocytic ehrli- 
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chiosis, and Ehrlichia ewingii, were identified as agents 
of newly recognized diseases in the United States, which 
were collectively termed the ehrlichioses [1-3]. Con- 
current infection with E. chaffeensis n an HIV-infected 
patient was first described in 1993, and subsequent re- 
ports have been sporadic [4-9]. Infections with the 
agent of human granulocytic ehrlichiosis or E. ewingii 
have not been described in this patient cohort. 
In persons infected with HIV, ehrlichiosis caused by 
E. chaffeensis i  often life threatening [4, 6, 7, 9]; how- 
ever, the disease responds well to specific therapy with 
tetracyclines, particularly when these antibiotics are 
given early in the course of the infection. In this report, 
we review and summarize the clinical courses and lab- 
oratory evaluations of 6 previously described patients 
and 15 newly reported patients who were coinfected 
with HIV and either E. chaffeensis or E. ewingii. 
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METHODS 
Identification of patients. Published cases of ehrlichiosis in 
persons infected with HIV were reviewed and summarized 
[4-9]. When available, supplementary clinical data were col- 
lected from the authors of these reports. Additional cases were 
identified passively in the course of routine patient care by 
infectious disease physicians practicing in clinics, hospitals, or 
medical centers in Arkansas, Florida, Georgia, Missouri, 
Oklahoma, and Tennessee from May 1997 through July 2000. 
Confirmed and suspected cases were reported to Centers for 
Disease Control and Prevention (CDC; Atlanta) during con- 
sultations or requests for confirmatory laboratory testing. Epi- 
demiological and clinical data for each patient were abstracted 
from clinic and hospital records. 
Laboratory confirmation. Clinical samples were obtained 
from patients during or shortly after their illnesses and tested 
using confirmatory assay(s). Peripheral blood, buffy coat, or 
bone marrow aspirate smears were stained with eosin-azure 
(Romanovsky)-type stains and examined for the presence of 
characteristic intracellular bacterial aggregates (morulae) in pa- 
tient leukocytes. Patient serum or plasma samples were eval- 
uated for antibodies reactive with E. chaffeensis by using indirect 
immunofluorescence assays (IFAs), as described elsewhere [10]. 
Nucleic acid amplification was done with DNA extracted from 
samples of whole blood, peripheral blood leukocyte preparations, 
serum, plasma, or bronchoalveolar lavage fluid, as described else- 
where [3, 11]. One or more genomic regions were amplified 
from extracted DNA using PCR assays. Regions of the 16S rRNA 
gene of E. chaffeensis were amplified with primer pairs HE1 and 
HE3 [12] or EhrlU (5'-AGAACGAACGCTGGCGGCAAG) and 
EhrlL (5'-TAGGTACCGTCATTATCTTCCCTA) in a direct as- 
say, or by a nested assay with primers 8F and 1448R in the 
primary reaction and primers HEl and GAIUR in the nested 
reaction [13]. Primers FB3 and FB5 were used to amplify the 
VLPT gene [11], and primers F1 and R2 were used to amplify 
the 120-kDa protein gene [14] of E. chaffeensis. Regions of the 
16S rRNA gene of E. ewingii were amplified directly by using 
primers EWF1 (5'-TCGAACGAACAATTCCTAAA) and HE3 or 
EWI and HE3 [3]. A region of the groESL heat-shock operon of 
E. ewingii was amplified in a nested PCR with primers HS1 and 
HS6 in the primary reaction and primers EWNFI and EWNR2 
in the nested reaction [15]. PCR products were evaluated by 
complete or by partial sequencing to verify identity, as described 
elsewhere [3, 11, 13, 15]. 
Formalin-fixed, paraffin-embedded bone marrow biopsy 
samples or autopsy tissues were stained with immunohisto- 
chemical stains, as described elsewhere [4, 16, 17]. For isolation 
of E. chaffeensis, peripheral blood leukocytes were separated 
from 3-5 mL of acute-phase whole blood and inoculated into 
DH82 cell cultures, as described elsewhere [7, 13]. The identity 
of each isolate was confirmed by means of PCR and sequencing. 
Statistical analyses. Significance tests were done with 
Fisher's exact test, for dichotomous variables, and the Mann- 
Whitney U test, for continuous variables; a P value of <.05 was 
considered significant. Analyses were done using SPSS software 
for Windows (SPSS) [18]. 
RESULTS 
Epidemiology and patient demographics. Ehrlichiosis was 
diagnosed in 21 HIV-infected patients during the period of 
1992-2000, including 17 patients in 1997-2000. Thirteen cases 
of disease were caused by E. chaffeensis, 4 by E. ewingii, and 4 
by either E. chaffeensis, E. ewingii, or an antigenically related 
Ehrlichia species. Patients infected with E. chaffeensis were iden- 
tified from northern Arkansas, southern Illinois, central Geor- 
gia, northern Florida, central and southern Missouri, and cen- 
tral Tennessee. Infections with E. ewingii were confirmed in 
patients from central and southern Oklahoma, southern Mis- 
souri, and central Tennessee. 
Twenty patients (95%) were male, and the median age was 43 
years (range, 31-56 years). Absolute CD4+ T lymphocyte counts 
were available for 20 patients; 14 patients (70%) had counts of 
<200 ceils/4L at or near the time that they presented for care. 
All patients but 1 had HIV infection diagnosed before they pre- 
sented with ehrlichiosis. In general, patients infected with E. 
chaffeensis had lower CD4+ T lymphocyte counts and had been 
aware of their HIV-seropositive status for fewer years than had 
patients infected with E. ewingii at the time they presented for 
care (table 1). Eleven patients (52%) had no prior opportunistic 
infection. For 5 patients (24%), oropharyngeal candidiasis had 
been the only prior infection associated with their immunode- 
ficiency. Severe or life-threatening opportunistic infections (e.g., 
Pneumocystis carinii pneumonia, Candida esophagitis, tubercu- 
losis, or disseminated infection with Mycobacterium avium) had 
occurred in 5 patients (24%) before the onset of their infection 
with an Ehrlichia species. According to the CDC surveillance 
classification for HIV infection, 14 patients presented with AIDS. 
Clinical categories were available for 20 patients in this series and 
included A2 (4 patients), A3 (7 patients), B2 (2 patients), B3 (3 
patients), and C3 (4 patients) [19]. 
Fourteen patients (67%) were receiving antibiotics that con- 
tained sulfa as chemoprophylaxis for P carinii. Approximately 
half of the patients were receiving combination antiretroviral 
regimens that included either a viral protease inhibitor or a 
nonnucleoside reverse transcriptase inhibitor (i.e., highly active 
antiretroviral therapy [HAART]). Four patients (19%) were not 
taking antiretroviral therapy at presentation (table 1). 
Onset of ehrlichial infections occurred from April through 
September of each year; 16 patients (76%) became ill during May 
or June. Eleven patients (52%) reported a recent tick bite and 8 
other patients (38%) had witnessed ticks on their clothing or on 
HIV/AIDS * CID 2001:33 (1 November) * 1587 
Table 1. Demographic and clinical characteristics of HIV infection in 21 patients with ehrlichiosis caused by Ehrlichia chaffeensis 
or Ehrlichia ewingii. 
Patients infected with 
E. chaffeensis E. ewingii All patients' 
Demographic or clinical parameter (n = 13) (n = 4) (n = 21) 
Age, median years (range) 41 (31-56) 46 (40-49) 43 (31-56) 
No. male 12 4 20 
Duration of known HIV seropositivity, median years (range) 4 (<1-13) 7 (1-11) 4 (<1-13) 
Most recent CD4+ cell count, median cells/LL (range)b 98 (13-462) 176 (106-226) 137 (13-462) 
HIV plasma RNA, median copies/mL (range)c 1950 (<50 to >750,000) 6736 (<50 to 231,380) 1900 (<50 to >750,000) 
No. with prior opportunistic infection 6 2 10 
No. receiving HAART 6 3 11 
NOTE. HAART, highly active antiretroviral therapy. 
a Includes 4 patients for whom specific ehrlichial agent could not be ascribed. 
b Data available for 20 patients. 
c Data available for 1 5 patients. 
pets or other persons in their household or neighborhood within 
days to weeks preceding the onset of illness. Activities associated 
with tick bites or presumed exposure included recreational pur- 
suits (hiking, camping, collecting arrowheads, fishing, picnicking, 
or canoeing) for 9 patients (47%); occupation (landscaping, field 
biology, gathering earthworms, or farming), for 6 patients (32%); 
and peridomestic activities (working or recreating in yard), for 
4 patients (2 1%). For 2 patients who had no identifiable recent 
tick exposure, presumptive xposures were associated with res- 
idence in or travel to rural or semirural areas. 
Clinical and laboratory characteristics. Patients presented 
for medical care a median of 4 days after the onset of illness 
(range, 1-21 days). All patients described fever as an initial 
component of their illnesses, and 13 patients presented with 
temperatures of :38.50C (median, 38.8?C; range, 36.30C- 
41.0?C). Patients infected with E. chaffeensis were more likely 
to present with :-1 gastrointestinal symptom, cough, or rash 
than were persons infected with E. ewingii (table 2). Rash pat- 
terns were described as diffusely erythematous or morbilliform, 
or scattered petechiae or macules. Rashes showed varied dis- 
tributions, from focal involvement of extremities to extensive 
involvement of chest and abdomen. All patients in this series 
presented with : 1 cytopenia, and thrombocytopenia was ob- 
served in all but 1 patient. Patients infected with E. chaffeensis 
were more likely to present with pancytopenia than were those 
infected with E. ewingii. Elevated hepatic aminotransferase l v- 
els were observed at presentation in all patients infected with 
E. chaffeensis but in only 2 (50%) of 4 patients infected with 
E. ewingii. Approximately 80% of all patients presented with 
mild to moderate hyponatremia (table 2). Less frequently noted 
electrolyte abnormalities included hypocalcemia, hypomagne- 
semia, and hypophosphatemia. 
Eighteen patients (86%) were hospitalized for their illnesses 
(table 3), with a median duration of stay of 6 days (range, 2-17 
days). Ehrlichiosis was considered among the differential di- 
agnoses within 24 h of evaluation for 13 patients (62%). Initial 
diagnoses other than ehrlichiosis included gastroenteritis (in 3 
patients), fever of undetermined etiology (in 3), pneumonia 
(in 2), unspecified viral syndrome (in 2), volume depletion (in 
2), urinary tract infection (in 1), pharyngitis (in 1), subdural 
Table 2. Selected initial signs, symptoms, and laboratory ab- 
normalities of ehrlichioses in patients coinfected with HIV. 
Patients infected with 
Ehrlichia Ehrlichia All 
chaffeensis ewingii patientsa 
Clinical characteristic (n = 13) (n = 4) (n = 21) 
Fever 13 (100) 4 (100) 21 (100) 
Malaise 10 (83) 2 (50) 15 (75) 
Myalgia 7 (58) 2 (50) 13 (65) 
Headache 5 (42) 1 (25) 10 (50) 
Cough 7 (58) 0 (0) 8 (40) 
Nausea 5 (42) 1 (25) 8 (40) 
Vomiting 5 (42) 1 (25) 8 (40) 
Diarrhea 5 (42) 0 (0) 6 (30) 
Rash 6 (46) 0 (0) 8 (38) 
Leukopenia 11 (88) 3 (75) 18 (86) 
Thrombocytopenia 13 (100) 3 (75) 20 (95) 
Anemia 8 (62) 3 (75) 12 (57) 
Pancytopenia 7 (54) 1 (25) 9 (43) 
Elevated aspartate amino- 
transferase level 13 (100) 2 (50) 18 (86) 
Elevated alanine amino- 
transferase level 10 (83) 1 (33) 11 (73) 
Hyponatremia 11 (85) 3 (75) 17 (81) 
NOTE. Data are no. (%). Percentages were calculated from patients for 
whom data were available. 
a Includes 4 patients for whom specific ehrlichial agent could not be ascribed. 
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Table 3. Comparison of clinical characteristics and laboratory results 
for HIV-infected patients coinfected with Ehrlichia chaffeensis or Ehr- 
lichia ewingii. 
Patients infected with 
Clinical characteristic or E. chaffeensis E. ewingii 
laboratory value (n = 13) (n = 4) pa 
No. hospitalized 12 2 .121 
No. of deaths 6 0 .237 
No. of patients with 
Pulmonary manifestationsb 8 0 .082 
Acute renal failure 6 0 .237 
Cardiac manifestationsc 5 0 .261 
Neurological manifestationsd 4 0 .519 
Disseminated intravascular 
coagulopathy 3 0 .541 
Spontaneous hemorrhage 3 0 .541 
Secondary fungal infection 3 0 .541 
Nadir WBC count, median 
x 109 cells/L (range) 1.8 (0.4-3.7) 3.4 (2.6-4.0) .003 
Nadir platelet count, median 
x 109 cells/L (range) 15 (2-42) 80 (34-255) .003 
Nadir hemoglobin level, me- 
dian g/L (range) 9.8 (8.2-13.8) 11.9 (7.9-12.2) .785 
Peak aspartate aminotransfer- 
ase level, median U/L 
(range) 293 (89-1107) 60 (23-131) .003 
Peak serum creatinine level, 
median mg/dL (range) 2.4 (1.0-9.0) 1.1 (0.7-1.4) .045 
Nadir serum sodium level, 
median mmol/L (range) 127 (121-134) 134 (132-135) .015 
a P values were determined using Fisher's exact test, for dichotomous variables, 
and Mann-Whitney U test, for continuous variables. 
b Includes acute respiratory distress syndrome, pneumonia, and acute hypoxia. 
c Includes atrial fibrillation, dilated cardiomyopathy, congestive heart failure, myo- 
carditis, and acute myocardial infarct. 
d Includes confusion, delirium, generalized seizures, and slurred speech. 
hemorrhage (in 1), and sepsis (in 1). For 8 patients (38%), 
ehrlichiosis was not considered until -4 days after initial eval- 
uation. All persons for whom a diagnosis of ehrlichiosis was 
considered received doxycycline within the first 24 h after pre- 
senting for care, and those who survived their illnesses generally 
became afebrile within 2-3 days after receiving this antibiotic. 
Moderate to severe disease manifestations were reported for 
15 patients (71%), predominantly among those infected with 
E. chaffeensis (table 3). Three (23%) of 13 patients infected with 
E. chaffeensis had acute respiratory distress syndrome diag- 
nosed, and 2 others developed pulmonary failure that required 
mechanical ventilatory support. Pulmonary, intracranial, or 
gastrointestinal hemorrhage occurred in 3 patients (23%) who 
were infected with E. chaffeensis. Secondary fungal infections, 
including pulmonary and tracheobronchial aspergillosis and 
tracheobronchial candidiasis, occurred in 3 E. chaffeensis- 
infected patients (23%) during the course of hospital stays that 
lasted 10 days. Hematologic and biochemical abnormalities 
were significantly more pronounced in persons infected with 
E. chaffeensis than they were in E. ewingii-infected patients 
(table 3). Platelet count nadirs of <50 X 109 cells/L were ob- 
served in 17 patients (8 1%) in this series; however, all 8 patients 
who had counts of <20 x 109 cells/L were infected with E. chaf- 
feensis. Similarly, all 7 patients who had serum sodium levels 
of <130 mmol/L and all 8 patients who had serum creatinine 
levels of >1.5 mg/dL were infected with this agent. 
Lumbar punctures were performed for 6 patients (29%). Three 
patients (50%) had mildly elevated WBC counts (range, 6- 
8 X 106 cells/L), with 85%-100% lymphocytes. Protein concen- 
tration was elevated in 4 patients (67%; range, 0.48-0.96 gIL). 
Cerebrospinal glucose levels were abnormally low (2.4 mmol/L) 
in 1 patient (17%) and elevated (4.5 mmolIL) in 1 patient. 
Six patients died either directly of infection with E. chaffeensis 
or of complications associated with the illness. All patients with 
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Table 4. Comparison of selected clinical events and characteristics associated with fatal 
and nonfatal infections with Ehrlichia chaffeensis in persons coinfected with HIV. 
Patients with 
Fatal Nonfatal 
E. chaffeensis E. chaffeensis 
infection infection 
Clinical event or characteristic (n = 6) (n = 7) pa 
Time from illness onset to presentation for 
medical care, median days (range) 3.5 (1-7) 4.0 (1- 6) .836 
Time from presentation to consideration of 
ehrlichiosis, median days (range) 5.5 (1-18) 1.0 (<1-5) .073 
CD4+ T lymphocyte count, median cells/,4L (range)b 64 (13-164) 232 (30-462) .088 
Receipt of ?1 antiretroviral drug 4 1 .102 
Receipt of HAART 1 5 .102 
Nadir platelet count of <20 x 109 cells/L 5 3 .266 
Peak serum creatinine level of >3.0 mg/dL 5 1 .029 
Peak aspartate aminotransferase level of >300 U/L 5 1 .029 
Nadir serum sodium level of <130 mmol/L 3 4 1.000 
NOTE. Data are no. of patients, unless otherwise indicated. HAART, highly active antiretroviral therapy. 
a Pvalues were determined using Fisher's exact test, for dichotomous variables, and Mann-Whitney Utest, 
for continuous variables. 
b Data available for 5 patients. 
fatal disease for whom CD4+ T lymphocyte counts were avail- 
able (5 patients) had counts of <200 cells/,uL; 4 patients (80%) 
had counts of <100 cells/,uL, and 2 patients (40%) had counts 
of <50 cellsl4AL. Case-fatality ratios for patients infected with 
E. chaffeensis at each of these CD4+ cell count break points 
were 62%, 67%, and 50%, respectively. Patients died a median 
of 13 days (range, 8-18 days) after the onset of symptoms. Four 
patients (67%) had been evaluated for their symptoms and 
released from at least 1 emergency room or medical clinic with 
a diagnosis other than ehrlichiosis within 1-2 weeks before 
admission. Most patients with fatal disease exhibited multi- 
system organ failure, including -2 of the following manifes- 
tations: acute renal failure (in 5 patients); pneumonia, severe 
hypoxia, or acute respiratory distress syndrome (in 4), atrial 
fibrillation or myocarditis (in 3); hepatic failure (in 3); meta- 
bolic acidosis (in 3); disseminated intravascular coagulopathy 
or spontaneous hemorrhage (in 3); and seizures or delirium 
(in 2). Specific causes of death included pulmonary hemor- 
rhage, pneumonia, respiratory failure, and cerebral edema with 
brainstem herniation. In general, patients with fatal E. chaf- 
feensis infections were more likely to have a later diagnosis of 
ehrlichiosis and develop acute renal failure, severe thrombo- 
cytopenia, and profound hepatic aminotransferase levations 
and were less likely to be taking HAART than were patients 
who recovered from infection with this agent; however, only 
peak creatinine levels of >3.0 mg/dL and aspartate aminotrans- 
ferase levels of >300 U/L were statistically significant predictors 
of fatal outcome (table 4). 
Laboratory confirmation. Infection with an Ehrlichia spe- 
cies was confirmed for each patient by using - 1 of the following 
laboratory results: amplification of gene sequences specific for 
an Ehrlichia species from a clinical sample (for 16 patients); 
?4-fold change in titer of antibodies reactive with E. chaffeensis 
antigens (for 12); immunohistochemical staining of E. chaf- 
feensis in biopsy or autopsy tissue specimens (for 3); morulae 
identified in peripheral blood or bone marrow leukocytes (for 
7); or isolation of E. chaffeensis in cell culture (for 6; table 5). 
For 16 patients (76%), ? 1 serum or plasma sample was 
obtained and tested for antibodies reactive with E. chaffeensis. 
Initial specimens (n = 4) obtained from patients with fatal 
disease were collected a median of 5 days after onset (range, 
4-15 days), and none had diagnostic IgG titers (i.e., -64). 
Initial samples (n = 12) obtained from patients who survived 
their infections were collected a median of 6.5 days after onset 
(range, 1-61 days), and 7 samples (58%) had titers of ?'64. 
Twelve (86%) of 14 patients from whom paired serum samples 
were obtained demonstrated a ?4-fold change in titer; 11 pa- 
tients (79%) had titers of >512 in the second sample, and these 
specimens were obtained a median of 41 days after onset (range, 
9-74 days). The geometric mean of the highest IgG antibody 
titer reactive with E. chaffeensis from the 9 patients for whom 
end points were available was 2048 (range, 512-16,384). Both 
patients with fatal disease for whom a second serum sample 
was available (obtained 8 days after onset of illness for one 
patient and 16 days after onset for the other) failed to develop 
anti-E. chaffeensis antibody titers of ?'64 before their deaths. 
A ?4-fold change in antibody titer reactive with E. chaffeensis 
was the only positive confirmatory test for 4 patients; however, 
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Table 5. Results of confirmatory tests for ehrlichioses in 21 patients coinfected with HIV. 
Patients infected with 
Ehrlichia Ehrlichia 
chaffeensis ewingii All patientsa 
Results of laboratory tests (n = 13) (n = 4) (n = 21) 
Ehrlichial DNA detected by use of PCR 12/12 4/4 16/18 
?4-fold change in titer of antibody reactive with E. chaffeensis 4/6 4/4 12/14 
Morulae identified in peripheral blood or bone marrow leukocytes 6/9 1/2 7/11 
Ehrlichiae identified in tissue by immunohistochemical stain 3/3 NT 3/3 
Ehrlichiae isolated in DH82 cells 6/6 0/1 6/7 
NOTE. Data are no. of patients with positive test result/no. tested. NT, none tested. 
a Includes 4 patients for whom specific ehrlichial agent could not be ascribed. 
because persons infected with either E. chaffeensis or E. ewingii 
may generate antibodies that react with E. chaffeensis antigens 
(in this series, 4 patients each), infection with these agents 
cannot be differentiated by using IFA as the sole confirmatory 
test [3, 15]. 
Morulae were visualized in peripheral blood or bone marrow 
leukocytes of '60% of patients in this series for whom whole 
blood, buffy coat, or bone marrow aspirate smears were eval- 
uated. When quantified, morulae of E. chaffeensis were iden- 
tified in -1%-25% of leukocytes, predominantly monocytes, 
and occasionally in metamyelocytes and band neutrophils. 
Morulae of E. ewingii were seen in -5% of mature and im- 
mature neutrophils and in rare eosinophils of 1 patient. 
Ehrlichial DNA was amplified from all but 2 patients tested; 
both negative specimens were acute-phase serum samples ob- 
tained from patients with ?'8-fold increases in antibody titer 
reactive with E. chaffeensis. Twelve samples yielded the charac- 
teristic 389-bp product from the 16S rRNA gene of E. chaffeensis 
when the DNAs were amplified by means of PCR. Appropriately 
sized fragments of the VLPT gene (369 bp, 459 bp, or 639 bp) 
and 120-kDa protein gene (-1250 bp or 1500 bp) were amplified 
from DNA samples from 6 patients from whom isolates of E. 
chaffeensis were obtained; fragments of identical sizes were ob- 
tained from the corresponding cell culture isolates. Sequenced 
PCR products from patients and isolates in all cases matched 
reported sequences for the corresponding enes of E. chaffeensis. 
A 354-bp segment of the 16S rRNA gene and a 1416-bp segment 
of the groESL heat-shock operon of E. ewingii were obtained 
from 2 patients by using nested PCR, and identities of these gene 
sequences were confirmed by sequencing. Expected 354-bp and 
389-bp segments of the 16S rRNA gene of E. ewingii were am- 
plified from the blood samples obtained from 2 additional pa- 
tients by use of PCR assays specific for E. ewingii. 
Antigens and distinct morulae of E. chaffeensis were identified 
by use of immunohistochemical staining in mononuclear cells 
of tissue specimens obtained from all 3 patients tested by means 
of this method. Ehrlichiae were visualized in various tissues 
and were especially abundant in bone marrow and spleen. 
E. chaffeensis was cultured from whole blood samples obtained 
from each of 6 patients for whom isolation was attempted. Blood 
samples ranged in age from 1 to 5 days and had been obtained 
from patients within 3-5 days after the onset of symptoms. Dis- 
tinct morulae were visible in DH82 cells within 2-8 days after 
inoculation of peripheral blood leukocytes. An attempt o isolate 
E. ewingii n DH82 cells was unsuccessful. 
DISCUSSION 
This report documents clinical, laboratory, and epidemiological 
features of ehrlichioses in 21 patients coinfected with HIV, oc- 
curring over broad geographic regions of the southeastern and 
midwestern United States. This is the first description of in- 
fections with E. ewingii in persons with HIV disease and the 
first report of laboratory-confirmed infections with E. ewingii 
in patients from Oklahoma and Tennessee. 
In the United States, ehrlichiae were first identified as human 
pathogens in 1986. Expanding public and physician awareness 
of and improved epidemiological surveillance for infections 
caused by Ehrlichia species have contributed to increasing rec- 
ognition of ehrlichioses in the general population. This is ex- 
emplified by recent increases in reported cases: -1200 cases of 
ehrlichioses were reported to state health departments from 
1986 through 1997 [20], but nearly 1300 cases were reported 
in 1998 and 1999 alone (CDC, unpublished data). Similarly, 
81% of the patients described in this series of HIV-infected 
patients were identified during the period of 1997-2000. How- 
ever, enhanced surveillance and awareness are perhaps only 2 
of several elements involved in the emergence of E. chaffeensis- 
and E. ewingii-associated illnesses in patients coinfected with 
HIV. Recent changes in the geographic distribution of persons 
with HIV disease and progress in the medical management of 
HIV-infected patients may also be contributing to the emer- 
gence of ehrlichioses in this patient population. 
Most patients in this series resided or worked in nonmetro- 
politan areas, which is true of the majority of persons who have 
ehrlichioses diagnosed [20, 21]. Although the absolute preva- 
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lence of HIV among persons in nonmetropolitan areas remains 
significantly lower than it is in urban centers, the number of 
HIV-infected persons residing in nonmetropolitan areas has 
increased steadily [22, 23]. From 1992 through 1995, the av- 
erage annual increase in AIDS cases in nonmetropolitan areas 
was 30.0%, which exceeded the 25.8% increase observed in the 
largest metropolitan areas [24]. The increase in HIV infection 
in rural populations has been attributed to increased trans- 
mission in these areas and to migration of persons to their 
native communities for treatment and supportive care after 
acquiring HIV infection in urban centers [25-27]. The diffusion 
of HIV into rural populations is particularly evident in the 
southeastern United States [25-29], which was the region with 
the greatest number of HIV infections during the mid-1990s 
[30]. This region also represents the origin of the majority of 
ehrlichiosis cases caused by E. chaffeensis [20]. 
Approximately half of the patients in this series were re- 
ceiving HAART, and most were in otherwise good health before 
the onset of their infection with an Ehrlichia species. Combi- 
nation antiretroviral regimens have significantly slowed the pro- 
gression of HIV disease in many persons, with concomitant 
decreases in the rates of hospitalization, morbidity, and mor- 
tality in patients for whom these drugs are available [30-33]. 
In this context, new therapies for HIV offer a level of health 
that facilitates occupational and recreational pursuits that per- 
haps were not previously possible. Some of these activities (e.g., 
hunting, hiking, camping, or working outdoors) involve in- 
cursions into tick-infested habitats and are associated with risks 
of acquiring tickborne diseases. Severe disease caused by Rick- 
ettsia rickettsii, the agent of Rocky Mountain spotted fever, and 
Babesia microti, an agent of human babesiosis, have been re- 
ported recently for persons with advanced HIV disease [34, 
35]. In this context, the emergence of a healthier HIV-infected 
patient population exposed to increasingly diverse environ- 
ments may paradoxically accentuate increases in the incidence 
of some infectious diseases, such as ehrlichioses. 
The full clinical spectrum of illnesses that result from infec- 
tions with E. chaffeensis or E. ewingii in HIV-infected patients 
may eventually reveal milder forms of disease; however, it is 
apparent that ehrlichioses, and illness caused by E. chaffeensis 
in particular, can be severe or life threatening in this patient 
cohort. All but 3 patients in this series were eventually hos- 
pitalized, creating a possible selection bias for those patients 
with more-severe disease; however, comparisons with other se- 
ries that include data for hospitalized patients suggest that ehr- 
lichiosis caused by E. chaffeensis more severe in HIV-infected 
persons than it is in the general population. In a series of 237 
patients from the general population that included 146 hos- 
pitalized persons (62%), renal failure, disseminated intravas- 
cular coagulopathy, spontaneous hemorrhages, or cardiac man- 
ifestations attributable to ehrlichiosis were identified in only 
3%-11% of persons infected with E. chaffeensis [21]. These 
same manifestations occurred in -15%-30% of the HIV-in- 
fected persons in this series. Contrasting mortality as a measure 
of disease severity, no deaths were reported among 41 patients 
hospitalized with E. chaffeensis infection described in separate 
prospective studies in Georgia, Missouri, North Carolina, and 
Tennessee from 1987 through 1998 [13, 36-38]; however, one- 
third of the hospitalized HIV-infected patients in this series 
died of infection with this agent. 
Severe disease attributable to E. chaffeensis has been described 
in patients with compromised immunity from other causes, 
including immunosuppressive therapies [39-42], monoclonal 
gammopathy [17], or asplenia [5, 43]. A resurgent T cell lym- 
phocytosis is frequently described in persons recovering from 
infection with E. chaffeensis [37, 44], suggesting that intact T 
cell host responses are important for clearance of ehrlichiae. In 
this series, all patients with fatal disease had CD4+ T lympho- 
cyte counts of <200 cells/4L. Case-fatality ratios for persons 
with <100 cells/,L were ?50%, in contrast with a case-fatality 
ratio in the general population of -3% [20]. In this context, 
ehrlichiae may represent opportunistic pathogens in HIV-in- 
fected persons. 
Only 4 patients infected with E. ewingii have been reported 
previously in the literature, and 3 of these had underlying im- 
munodeficiencies [3]. It is unclear whether E. ewingii causes 
disease primarily in immunosuppressed persons or if this bac- 
terium is responsible for illnesses in a broader patient popu- 
lation, in which only the most clinically advanced cases have 
been recognized in a sentinel cohort. Only 2 (50%) of 4 patients 
with confirmed E. ewingii infection in this series were hospi- 
talized, and all patients recovered completely from infection 
with this pathogen. The E. ewingii-infected patients reported 
in this series developed fewer disease manifestations and com- 
plications than did patients infected with E. chaffeensis. Al- 
though these findings suggest that E. ewingii may be less path- 
ogenic than E. chaffeensis, the small number of patients 
evaluated to date precludes broad comparisons of severity be- 
tween these 2 forms of ehrlichiosis in this patient population. 
Host factors responsible for disease severity remain relatively 
undefined in persons infected with E. chaffeensis [7, 13]. A wide 
range of clinical outcomes was recognized soon after the initial 
identification of human ehrlichiosis in the United States [45]; 
a spectrum of disease severity continues to be observed among 
persons infected with ehrlichiae. Severe and sometimes fatal 
illnesses have occurred in otherwise healthy young adults and 
children [5, 9, 46]. In contrast, relatively moderate disease 
caused by E. chaffeensis or E. ewingii occurred in several HIV- 
infected patients in this series, including some patients with 
CD4+ T lymphocyte counts of <200 cells/,uL. Genetic hetero- 
geneity exists among different isolates of F. chaffeensis [7, 11, 
13, 14], which suggests that different strains of this bacterium 
1592 - CID 2001:33 (1 November) * HlV/AlDS 
may vary in phenotypic or biological characteristics that influ- 
ence pathogenicity [7, 13]. Other studies have demonstrated 
that factors extrinsic to the host or pathogen, particularly delay 
in treatment with an appropriate antibiotic (e.g., a tetracycline), 
can be associated with an increased risk for disease compli- 
cations and death in persons infected with ehrlichiae [21]. A 
combination of factors, including the immune status of the 
patient, the interval from symptom onset to correct diagnosis 
and initiation of effective therapy, and, perhaps, the virulence 
of the bacterial isolate infecting the patient, may ultimately 
represent important and interacting determinants of the clinical 
outcome of ehrlichioses. 
Most presenting signs and symptoms (e.g., fever, headache, 
malaise, myalgia, and nausea) were nonspecific and similar in 
frequency to those described in other case series of patients 
infected with E. chaffeensis or E. ewingii [3, 21, 37, 43, 47]. 
Diagnosis of ehrlichioses in persons coinfected with HIV may 
be confounded by clinical similarity with various community- 
acquired or conventionally recognized opportunistic infections 
in this patient population. As with many other systemic diseases 
in persons infected with HIV, ehrlichioses may present with 
multiple and varied signs and symptoms, including vomiting, 
diarrhea, rash, or cough. Leukopenia, thrombocytopenia, and 
anemia occurred with frequencies imilar to those described in 
prospective series of E. chaffeensis-infected patients in the gen- 
eral population; however, median nadir values for each value 
were markedly lower in HIV-infected patients [13, 36, 37, 47]. 
Cytopenia, although a characteristic finding of ehrlichioses, is 
perhaps less indicative of these illnesses in HIV-infected patients 
than it is in the general population, and it can be caused by 
HIV disease, other opportunistic infections, or various anti- 
microbial therapies used by this patient cohort [48, 49]. 
Several of the patients in this series initially had other con- 
ditions diagnosed, and one-third of the patients received em- 
pirical therapy with 1 antibiotic that was ineffective against 
ehrlichiae (e.g., cephalosporins, macrolides, and sulfa antimicro- 
bials). Doxycycline, the drug of choice for ehrlichioses, is not 
routinely administered as empirical therapy for febrile patients 
infected with HIV. Two-thirds of the patients were receiving tri- 
methoprim-sulfamethoxazole or dapsone as chemoprophylaxis 
for R carinii pneumonia at the time of their illness. It has been 
suggested that drugs that contain sulfa may exacerbate the se- 
verity of infection with E. chaffeensis [50]; however, further stud- 
ies are necessary to confirm this observation. 
Several patients who died of infection with E. chaffeensis 
failed to mount IgG antibody responses by week 2 or 3 of 
illness; however, most patients in this series showed antibody 
responses that are similar both temporally and in magnitude 
to those observed in the general population [13, 36, 51]. All 
patients who survived their illness developed robust IgG an- 
tibody levels, including some patients with CD4+ T lymphocyte 
counts of <200 cells/,uL. As noted in earlier studies, diagnostic 
levels of IgG antibodies were not present in the first serum 
sample obtained from the majority of acutely ill patients in this 
series. Restricting serological evaluation to a single sample ob- 
tained during the acute phase of the illness may preclude lab- 
oratory confirmation of ehrlichioses [51]. For 4 patients, lab- 
oratory confirmation was obtained by using IFA as the only 
test. Patients infected with either E. chaffeensis or E. ewingii 
may demonstrate ?4-fold changes in titers of antibodies re- 
active with E. chaffeensis; this finding may prevent assignment 
of a specific agent if IFA is used as the sole confirmatory test 
[3, 15]. In this context, testing multiple samples by use of a 
combination of serological and molecular assays may be nec- 
essary to confirm the disease and to ascribe a species-specific 
etiology. 
Successful outcomes after Ehrlichia-associated illnesses in 
HIV-infected patients can be achieved by using fundamental 
principles that apply to successful management of ehrlichioses 
in the general population. In this context, improving awareness 
among physicians and patients of the seasonal and geographic 
distribution of diseases caused by Ehrlichia species, eliciting 
pertinent epidemiological data in the patient history (e.g., a 
recent tick bite or exposure to ticks), and using an early pre- 
sumptive diagnosis to guide empirical treatment with doxy- 
cycline remain the best approaches to combat these potentially 
fatal diseases. 
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